

## RECENT ADVANCES AGAINST BLOOD CANCERS

In the 12 months from August 1, 2019 to July 31, 2020, the U.S. Food and Drug Administration made numerous decisions that are transforming the lives of patients with a wide array of hematologic cancers, including the following:

### Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

- Acalabrutinib (Calquence) is a molecularly targeted therapeutic approved in November 2019.

### Follicular Lymphoma

- Tazemetostat (Tazverik) is a molecularly targeted therapeutic approved in June 2020.

### Multiple Myeloma

- Isatuximab-irfc (Sarclisa) is an immunotherapeutic approved in March 2020 for use in combination with pomalidomide (Pomalyst) and dexamethasone.

### Myelofibrosis

- Fedratinib (Inrebic) is a molecularly targeted therapeutic approved in August 2019.

### Diffuse Large B-cell Lymphoma

- Selinexor (Xpovio) is a molecularly targeted therapeutic approved in June 2020.
- Tafasitamab-cxix (Monjuvi) is an immunotherapeutic approved in July 2020.

### Mantle Cell Lymphoma

- Brexucabtagene autoleucel (Tecartus) is an immunotherapeutic approved in July 2020.
- Zanubrutinib (Zankinsa) is a molecularly targeted therapeutic approved in November 2019.

### Myelodysplastic Syndrome

- Inqovi is a tablet containing decitabine and cedazuridine approved in July 2020.

